DentalGoodNews|Dental Credible Information Platform


普特医疗:2024年营收1.96亿元,同比下降4.39%

 
Issuing time:2025-05-08 12:33Author:编辑部
image.png
*图源:普特医疗2024年年度报告

好的牙·讯|浙江普特医疗器械股份有限公司(以下简称“普特医疗”)近日发布2024年年度报告。报告显示,2024年公司实现营业收入1.96亿元,同比下降4.39%;归属于挂牌公司股东的净利润0.73亿元,同比下降12.12%。

image.png
*图源:普特医疗2024年年度报告

按产品分类看,正畸托槽实现营收1.52亿元,同比下降6.25%,毛利率为82.47%;口腔植入材料实现营收0.14亿元,同比下降18.39%,毛利率为76.24%。

image.png
*图源:普特医疗2024年年度报告

按地区来看,内销渠道实现营收1.61亿元,同比下降5.86%;外销渠道实现营收0.35亿元,同比增长2.97%。

image.png
*图源:普特医疗2024年年度报告

成本费用方面,2024年公司营业成本为0.44亿元,同比下降1.52%;毛利率为77.69%,较上年同期下降0.65%。

期间销售费用为0.40亿元,同比下降4.59%;管理费用为0.18亿元,同比增长28.10%,主要系管理人员薪酬、挂牌相关中介机构费用以及股份支付费用增加所致;研发费用为0.11亿元,同比下降7.42%。

image.png
*图源:普特医疗2024年年度报告

现金流方面,2024年公司经营活动产生的现金流量净额为0.73亿元,同比下降6.95%;投资活动产生的现金流量净额为-0.79亿元;筹资活动产生的现金流量净额为-0.21亿元,主要系在报告期内分配了上年度股利所致。

image.png
*图源:普特医疗2024年年度报告

资产负债方面,截至2024年末,公司总资产为4.29亿元,同比增长13.13%;负债总额为0.32亿元,同比下降15.82%;资产负债率为7.45%,较上年期末的10.02%有所下降。

报告期内,公司持续加强创新研发,截至年末拥有111项专利,其中发明专利8项、实用新型专利82项、外观设计专利21项。

展位未来,公司将继续关注市场动态和行业政策变化,应对行业监管、政策变化、市场竞争加剧等风险,保持竞争优势和可持续发展。

Member Trending Reads

Member Trending Reads

副标题

Full - mouth denture restoration is included in medical insurance. The industry concentration is at a low level, and there is huge room for integration. Are you ready to embrace new opportunities?
Regulation: Not to restrict growth, but to weed out bad apples & protect good ones—let quality firms shine in fair competition!
"Cooling Momentum, Unwavering Resilience" – The Dental Industry Is Marching Toward "Quality Restoration"!
California's New Bill Sets Clear Boundaries for Dentists' Decision-Making Authority: How to Balance Clinical Autonomy Amid the Capitalization Wave?
Mental Health: A Casualty of the Healthcare System — Who Foots the Bill for Practitioners’ Physical & Mental Well-Being?
National Dental Expansion Rebounds | 940 Net New (Sep)—What’s the Future Potential?
Standardized Implants → Millimeter-Level Orthognathic Bone Resection: Robots Reshaping Dental Surgery’s Execution Logic & Tech Boundaries!
【GOODNEWS】 Content for industry reference only (based on public info & professional judgment); not for decision-making. Readers bear full responsibility for their own judgment and risks. Copyright © This Platform. Unauthorized reproduction & commercial use prohibited. Errata, contributions & cooperation: Contact customer service via WeChat:HDSW_001
✉️
Subscribe to Our
Newsletter
We curate important stories and exclusive insights, delivered straight to your inbox.
In-depth analysis · Exclusive content · Fast-moving news
1
Contact Us


Cooperation & Contact: haodeya@dongxizixun.com
Industry Updates

Industry Updates

副标题